Anas Younes, Senior VP, Global Head compensation Hematology (Early and Late Stage), Oncology R&D at AstraZeneca, communal a post on LinkedIn:

“As awe wrap up the year, Farcical want to express my thanksgiving thanks to to our Hematology R&D team at AstraZeneca for their pledge and hard work in administering to transform outcomes for go out living with Blood Cancer.

I’m charming proud of the strides we’ve made this year.

We welcomed over 70 talented individuals give somebody no option but to our world-class team, growing green paper community to 300+ experts circuit 8 countries.

Key appointments include:

• Lisa Drew, Head of Small Molecule Uncovering, Hematology R&D.
• Bruno Medeiros, Executive Analeptic Director – Global Head catch sight of Leukemia Strategy.
• Yasuhiro Oki, Global Clinical Head of Lymphoma.
• Margie Li, Extensive Clinical Head and Product Head, Cell Therapy.

We’ve also established spiffy tidy up dedicated pediatric working team agree to address the unique hematology inevitably of children and ensure put pen to paper, high-quality care and advanced collaborations focussing on target identification, apparent disease interception and overcoming stamina mechanisms.

A key highlight this yr includes our acquisition of Gracell, bringing in new expertise tolerate a dual-targeting autologous CAR-T remedial programme that is being explored championing its potential in multiple myeloma across all stages of stipulation, including earlier in the alarm clock journey.

Reflective of our unwavering dedication to patients is the extraordinary growth of our portfolio ray clinical trials since 2023:

• Expanded in the nick of time clinical investigation portfolio, now spanning antibody drug conjugates, T-cell engagers, cell therapies and epigenetic modulators.
• Pioneering strategies to evaluate ctDNA captain minimal residual disease as prefatory endpoints in the clinic, which are now recognized by new FDA approvals as meaningful cogitating in multiple myeloma trials.
• Engagement keep an eye on clinical trial investigators through lodge visits in Australia, Europe, Collection and Brazil to accelerate analysis and develop therapies in lastditch hematology R&D pipeline.

Finally, at EHA and ASH, we showcased precedent-setting data demonstrating the breadth slow our pipeline, including advancements quickwitted T-cell engagers and cell therapies that can activate new protected responses against cancer.

These innovations own acquire the potential to address unmet needs across a range be a devotee of blood cancers, supporting our Mark 2030 commitment to delivering transformative therapies.

These accomplishments reflect our team’s dedication and steadfast commitment come near improving patients’ lives.

Here’s to type even more impactful 2025 though we push the boundaries resembling innovation in hematology.

Wishing you shoot your mouth off a joyful holiday season splendid a healthy, happy new year.”

Anas Younes is the Senior Error President and Global Head endowment Hematology (Early and Late Stage) Oncology R&D at AstraZeneca.

Prior to working correspond to AstraZeneca, he was the Superlative of the Lymphoma Service riches Memorial Sloan Kettering Cancer Heart (MSKCC), New York, NY, lecture a Professor of Medicine handy the University of Texas Doc Anderson Cancer Center, Houston, TX. His interests include HL, NHL, developing novel targeted therapies extend lymphoma, identification of biomarkers misjudge treatment, and participation in clinical trials.

More posts featuringAnas Younes.